Biblio
Export 351 results:
Author Title Type [ Year] Filters: First Letter Of Title is C [Clear All Filters]
“Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
, “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
, “Cognitive reserve in ageing and Alzheimer's disease.”, Lancet Neurol, vol. 11, no. 11, pp. 1006-12, 2012.
, “C9orf72 nucleotide repeat structures initiate molecular cascades of disease.”, Nature, vol. 507, no. 7491, pp. 195-200, 2014.
, “Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).”, J Alzheimers Dis, vol. 46, no. 3, pp. 687-93, 2015.
, “Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 47, no. 4, pp. 1009-19, 2015.
, “Cognitive Function and Its Relationship with Macular Pigment Optical Density and Serum Concentrations of its Constituent Carotenoids.”, J Alzheimers Dis, vol. 48, no. 1, pp. 261-77, 2015.
, “Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.”, J Alzheimers Dis, vol. 47, no. 1, pp. 205-14, 2015.
, “Comorbid Depression and Diabetes as a Risk for Mild Cognitive Impairment and Alzheimer's Disease in Elderly Mexican Americans.”, J Alzheimers Dis, vol. 47, no. 1, pp. 129-36, 2015.
, “Comprehensive Gene- and Pathway-Based Analysis of Depressive Symptoms in Older Adults.”, J Alzheimers Dis, 2015.
, “The Continuing Failure of Bexarotene in Alzheimer's Disease Mice.”, J Alzheimers Dis, 2015.
, “Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, , , “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
, “Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+).”, J Alzheimers Dis, vol. 49, no. 1, pp. 149-57, 2016.
, “Cerebral Amyloid Angiopathy (CAA)-Related Inflammation: Comparison of Inflammatory CAA and Amyloid-β-Related Angiitis.”, J Alzheimers Dis, vol. 51, no. 2, pp. 525-32, 2016.
, “Cerebral Arterial Occlusion Did Not Promote the Prevalence of Cerebral Amyloid Angiopathy.”, J Alzheimers Dis, vol. 54, no. 1, pp. 269-74, 2016.
, “Cerebral Glucose Metabolism is Associated with Verbal but not Visual Memory Performance in Community-Dwelling Older Adults.”, J Alzheimers Dis, vol. 52, no. 2, pp. 661-72, 2016.
, “Cerebral Microbleeds and Cerebrovascular Reactivity in the General Population: The EDAN Study.”, J Alzheimers Dis, vol. 53, no. 2, pp. 497-503, 2016.
, “Cerebral Small Vessel Disease and Motoric Cognitive Risk Syndrome: Results from the Kerala-Einstein Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 699-707, 2016.
, “Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 1, pp. 351-7, 2016.
, “Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.”, J Alzheimers Dis, vol. 54, no. 1, pp. 287-95, 2016.
, “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 3, pp. 759-64, 2016.
, “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1291-1295, 2016.
,